These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35841285)

  • 1. Pityriasis lichenoides chronica after BNT162b2 Pfizer-BioNTech vaccine: A novel cutaneous reaction after SARS-CoV-2 vaccine.
    Drago F; Ciccarese G; Guadagno A; Parodi A
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e979-e981. PubMed ID: 35841285
    [No Abstract]   [Full Text] [Related]  

  • 2. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine.
    Sechi A; Pierobon E; Pezzolo E; Germi L; Trevisan G; Zardo D; Riva G; Mondino S; Naldi L
    Clin Exp Dermatol; 2022 Feb; 47(2):437-440. PubMed ID: 34617317
    [No Abstract]   [Full Text] [Related]  

  • 3. Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption.
    Sernicola A; Dybala A; Gomes V; Maddalena P; Adotti F; Soda G; Muharremi R; Fino P; Del Duca E; Grieco T
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):e172-e174. PubMed ID: 34751995
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.
    Cebeci Kahraman F; Savaş Erdoğan S; Aktaş ND; Albayrak H; Türkmen D; Borlu M; Arıca DA; Demirbaş A; Akbayrak A; Polat Ekinci A; Gökçek GE; Çelik HA; Taşolar MK; An İ; Temiz SA; Hazinedar E; Ayhan E; Hızlı P; Solak EÖ; Kılıç A; Yılmaz E
    J Cosmet Dermatol; 2022 Sep; 21(9):3692-3703. PubMed ID: 35780311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty
    Ando M; Satonaga Y; Takaki R; Yabe M; Kan T; Omote E; Yamasaki T; Komiya K; Hiramatsu K
    Int J Infect Dis; 2022 Nov; 124():187-189. PubMed ID: 36122668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine.
    Basile K; Rockett RJ; McPhie K; Fennell M; Johnson-Mackinnon J; Agius JE; Fong W; Rahman H; Ko D; Donavan L; Hueston L; Lam C; Arnott A; Chen SC; Maddocks S; O'Sullivan MV; Dwyer DE; Sintchenko V; Kok J
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination.
    Algaissi A; Alamer E; Jeraiby M; Alomaish A; Elrhima O; Qumayi S; Qasir NA; Areeshi H; Masmali A; Alhazmi A
    Saudi Med J; 2022 Jun; 43(6):567-571. PubMed ID: 35675927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2.
    Ramot Y; Nanova K; Faitatziadou SM; Assab DA; Berkun Y; Zlotogorski A
    J Dtsch Dermatol Ges; 2022 Aug; 20(8):1123-1124. PubMed ID: 35698860
    [No Abstract]   [Full Text] [Related]  

  • 10. A definite case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by administration of the Pfizer/BioNTech BNT162b2 vaccine for SARS-CoV2.
    Schroeder JW; Gamba C; Toniato A; ; Rongioletti F
    Clin Dermatol; 2022; 40(5):591-594. PubMed ID: 35550918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated herpes zoster in an immune-competent patient after SARS-CoV-2 vaccine (BNT162b2 Comirnaty, Pfizer).
    Zengarini C; Misciali C; Ferrari T; Dika E; La Placa M; Piraccini BM; Baraldi C
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e622-e623. PubMed ID: 35429051
    [No Abstract]   [Full Text] [Related]  

  • 13. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
    Lavery MJ; Nawimana S; Parslew R; Stewart L
    Clin Exp Dermatol; 2021 Oct; 46(7):1325-1327. PubMed ID: 33914926
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral lesions postinjection of the first administration of Pfizer-BioNTech SARS-CoV-2 (BNT162b2) vaccine.
    Manfredi M; Ghidini G; Ridolo E; Pizzi S
    Oral Dis; 2022 Nov; 28 Suppl 2():2605-2607. PubMed ID: 33978308
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine.
    Luo A; Oakley A
    Australas J Dermatol; 2022 Aug; 63(3):e247-e250. PubMed ID: 35607272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study: authors' response.
    Shasha D; Heymann AD; Zacay G
    Clin Microbiol Infect; 2022 Mar; 28(3):454-455. PubMed ID: 34923127
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine.
    Giuffrida G; Condorelli A; Di Giorgio MA; Markovic U; Sciortino R; Nicolosi D; Di Raimondo F
    Haematologica; 2022 Apr; 107(4):1008-1010. PubMed ID: 34382388
    [No Abstract]   [Full Text] [Related]  

  • 19. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine.
    Hunjan MK; Roberts C; Karim S; Hague J
    Clin Exp Dermatol; 2022 Jan; 47(1):188-190. PubMed ID: 34379821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study' by Shasha et al.
    Scorza FA; Finsterer J
    Clin Microbiol Infect; 2022 Mar; 28(3):452-453. PubMed ID: 34839005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.